StockData
Gilead Sciences, Inc. logo

Gilead Sciences, Inc.

GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.33−0.35 (-0.21%)

Close on Nov 2, 2026Market cap $211.20BP/E –Yield 1.86%

Gilead Sciences GAAP product gross margin by Year

GAAP product gross margin (%) (%)

Gilead Sciences GAAP product gross margin: 78.4% in FY2025, up 0.2 pts from a year earlier.

Latest, FY2025
78.4%
Period ended Dec 31, 2025
Change on a year earlier
+0.2 pts
78.2% in FY2024
History
10 years
Since FY2016
Sources
9
Documents cited below

Where the FY2025 figure comes from

“|| GAAP product gross margin | 79.5 | % | 79.0 | % | 78.4 | % | 78.2 | %”

Source: Form 8-K (exhibit991earningspressrel.htm, filed 2026-02-10) ↗

Reported in Form 10-Q / 10-K & Form 8-K.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

Cite this data

StockData. (2026). Gilead Sciences GAAP product gross margin (%), annual FY2016–FY2025 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/gaap-gross-margin-pct

See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.